CellProthera to share results from its Phase I/IIb study investigating the safety and efficacy of ProtheraCytes (CD34+ expanded stem cells) in acute myocardial infarction

Mulhouse, France, April 23, 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will share, for the first-time, promising results from EXCELLENT Phase I/IIb study aiming to assess the safety and efficacy of transendocardial injection of autologous expanded CD34+ stem cells, labelled ProtheraCytes®, after Acute Myocardial Infarction. The Phase I/IIb study was performed in 13 sites in the UK and France and has enrolled 49 patients with persistent left ventricle dysfunction following acute myocardial infarction. Patients were randomized to either standard of care (SoC) alone or in combination with ProtheraCytes.

The results of the study will be presented by Prof. Faiez Zannad, Emeritus Professor of Therapeutics at the Université of Lorraine and chairman of the Study’s steering committee, on May 14^th at Heart Failure 2024 in Lisbon. The results will detail the findings at six months, in particular, the positive changes from baseline of cardiac function and viability parameters assessed with MRI.

“Despite optimal guideline-based therapy, Acute Myocardial Infarction frequently leads to the development of chronic heart failure and 5% to 10% of patients will experience mortality within the first 12 months. Therefore, new treatments are needed to further improve the management of these patients and the cardiac regenerative therapy developed by CellProthera emerges as a promising option,” says Prof Faiez Zannad.

About CellProthera

CellProthera is a clinical-stage regenerative cell therapy developer specializing in ischemic diseases. CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of a large quantity of purified CD34+ stem cells. Its lead therapy, ProtheraCytes®, is an autologous cell therapy that has been developed for tissue reperfusion and salvage of damaged cardiac tissue. ProtheraCytes® is registered as an Advanced Therapy Medicinal Product by the European Medicine Agency (EMA). CellProthera’s proprietary technology platform includes StemXpand®, an automated expansion device, and its single-use StemPack® cell culture kits. CellProthera is headquartered in France. For more information, visit cellprothera.com.

Mulhouse, France, April 23, 2024 – CellProthera, a regenerative cell therapy developer specializing in ischemic diseases will share, for the first-time, promising results from EXCELLENT Phase I/IIb study aiming to assess the safety and efficacy of transendocardial injection of autologous expanded CD34+ stem cells, labelled ProtheraCytes®, after Acute Myocardial Infarction. The Phase I/IIb study was performed in 13 sites in the UK and France and has enrolled 49 patients with persistent left ventricle dysfunction following acute myocardial infarction. Patients were randomized to either standard of care (SoC) alone or in combination with ProtheraCytes.

The results of the study will be presented by Prof. Faiez Zannad, Emeritus Professor of Therapeutics at the Université of Lorraine and chairman of the Study’s steering committee, on May 14^th at Heart Failure 2024 in Lisbon. The results will detail the findings at six months, in particular, the positive changes from baseline of cardiac function and viability parameters assessed with MRI.

“Despite optimal guideline-based therapy, Acute Myocardial Infarction frequently leads to the development of chronic heart failure and 5% to 10% of patients will experience mortality within the first 12 months. Therefore, new treatments are needed to further improve the management of these patients and the cardiac regenerative therapy developed by CellProthera emerges as a promising option,” says Prof Faiez Zannad.

About CellProthera

CellProthera is a clinical-stage regenerative cell therapy developer specializing in ischemic diseases. CellProthera has developed a unique GMP-compliant cell expansion process as well as a proprietary automation technology for in vitro production of a large quantity of purified CD34+ stem cells. Its lead therapy, ProtheraCytes®, is an autologous cell therapy that has been developed for tissue reperfusion and salvage of damaged cardiac tissue. ProtheraCytes® is registered as an Advanced Therapy Medicinal Product by the European Medicine Agency (EMA). CellProthera’s proprietary technology platform includes StemXpand®, an automated expansion device, and its single-use StemPack® cell culture kits. CellProthera is headquartered in France. For more information, visit cellprothera.com.